Nicole Bertoletti, PhD
Associate Research Scientist in Pharmacology
Research & Publications
Biography
Locations
Coauthors
Selected Publications
- Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV‐1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabineBertoletti N, Chan AH, Schinazi RF, Yin YW, Anderson KS. Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV‐1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine. Protein Science 2019, 28: 1664-1675. PMID: 31301259, PMCID: PMC6699100, DOI: 10.1002/pro.3681.
- Cryo-EM analyses of KIT and oncogenic mutants reveal structural oncogenic plasticity and a target for therapeutic interventionKrimmer S, Bertoletti N, Suzuki Y, Katic L, Mohanty J, Shu S, Lee S, Lax I, Mi W, Schlessinger J. Cryo-EM analyses of KIT and oncogenic mutants reveal structural oncogenic plasticity and a target for therapeutic intervention. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2300054120. PMID: 36943885, PMCID: PMC10068818, DOI: 10.1073/pnas.2300054120.
- New Insights into Human 17β-Hydroxysteroid Dehydrogenase Type 14: First Crystal Structures in Complex with a Steroidal Ligand and with a Potent Nonsteroidal InhibitorBertoletti N, Braun F, Lepage M, Möller G, Adamski J, Heine A, Klebe G, Marchais-Oberwinkler S. New Insights into Human 17β-Hydroxysteroid Dehydrogenase Type 14: First Crystal Structures in Complex with a Steroidal Ligand and with a Potent Nonsteroidal Inhibitor. Journal Of Medicinal Chemistry 2016, 59: 6961-6967. PMID: 27362750, DOI: 10.1021/acs.jmedchem.6b00293.
- Structural Studies and Structure Activity Relationships for Novel Computationally Designed Non-nucleoside Inhibitors and Their Interactions With HIV-1 Reverse TranscriptaseFrey KM, Bertoletti N, Chan AH, Ippolito JA, Bollini M, Spasov KA, Jorgensen WL, Anderson KS. Structural Studies and Structure Activity Relationships for Novel Computationally Designed Non-nucleoside Inhibitors and Their Interactions With HIV-1 Reverse Transcriptase. Frontiers In Molecular Biosciences 2022, 9: 805187. PMID: 35237658, PMCID: PMC8882919, DOI: 10.3389/fmolb.2022.805187.
- Covalent Inhibition of Wild-Type HIV‑1 Reverse Transcriptase Using a Fluorosulfate WarheadIppolito JA, Niu H, Bertoletti N, Carter ZJ, Jin S, Spasov KA, Cisneros J, Valhondo M, Cutrona KJ, Anderson KS, Jorgensen WL. Covalent Inhibition of Wild-Type HIV‑1 Reverse Transcriptase Using a Fluorosulfate Warhead. ACS Medicinal Chemistry Letters 2021, 12: 249-255. PMID: 33603971, PMCID: PMC7883463, DOI: 10.1021/acsmedchemlett.0c00612.
- Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug ResistanceBertoletti N, Chan AH, Schinazi RF, Anderson KS. Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug Resistance. Molecules 2020, 25: 4868. PMID: 33096918, PMCID: PMC7587939, DOI: 10.3390/molecules25204868.
- Structure-Guided Identification of DNMT3B InhibitorsNewton AS, Faver JC, Micevic G, Muthusamy V, Kudalkar SN, Bertoletti N, Anderson KS, Bosenberg MW, Jorgensen WL. Structure-Guided Identification of DNMT3B Inhibitors. ACS Medicinal Chemistry Letters 2020, 11: 971-976. PMID: 32435413, PMCID: PMC7236258, DOI: 10.1021/acsmedchemlett.0c00011.
- Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIVKudalkar SN, Ullah I, Bertoletti N, Mandl HK, Cisneros JA, Beloor J, Chan AH, Quijano E, Saltzman WM, Jorgensen WL, Kumar P, Anderson KS. Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV. Antiviral Research 2019, 167: 110-116. PMID: 31034849, PMCID: PMC6554724, DOI: 10.1016/j.antiviral.2019.04.010.
- Mutational and structural studies uncover crucial amino acids determining activity and stability of 17β-HSD14Badran M, Bertoletti N, Keils A, Heine A, Klebe G, Marchais-Oberwinkler S. Mutational and structural studies uncover crucial amino acids determining activity and stability of 17β-HSD14. The Journal Of Steroid Biochemistry And Molecular Biology 2019, 189: 135-144. PMID: 30836176, DOI: 10.1016/j.jsbmb.2019.02.009.
- DRONE: Direct Tracking of DNA Cytidine Deamination and Other DNA Modifying ActivitiesSasaki T, Kudalkar SN, Bertoletti N, Anderson KS. DRONE: Direct Tracking of DNA Cytidine Deamination and Other DNA Modifying Activities. Analytical Chemistry 2018, 90: 11735-11740. PMID: 30256094, PMCID: PMC6410358, DOI: 10.1021/acs.analchem.8b01405.
- Structure-based design and profiling of novel 17β-HSD14 inhibitorsBraun F, Bertoletti N, Möller G, Adamski J, Frotscher M, Guragossian N, Gírio P, Le Borgne M, Ettouati L, Falson P, Müller S, Vollmer G, Heine A, Klebe G, Marchais-Oberwinkler S. Structure-based design and profiling of novel 17β-HSD14 inhibitors. European Journal Of Medicinal Chemistry 2018, 155: 61-76. PMID: 29859505, DOI: 10.1016/j.ejmech.2018.05.029.
- Validation of a 96-fragment library for crystallographic screeningHeine A, Siefker C, Abazi N, Glöckner S, Bertoletti N, Hassaan E, Magari F, Metz A, Weiss M, Klebe G. Validation of a 96-fragment library for crystallographic screening. Acta Crystallographica Section A: Foundations And Advances 2017, 73: c95-c95. DOI: 10.1107/s2053273317094761.
- X-ray crystallography: essential tool for protein characterization and ligand optimizationBertoletti N, Braun F, Metz A, Heine A, Klebe G, Marchais-Oberwinkler S. X-ray crystallography: essential tool for protein characterization and ligand optimization. Acta Crystallographica Section A: Foundations And Advances 2017, 73: c234-c234. DOI: 10.1107/s2053273317093391.
- First Structure–Activity Relationship of 17β-Hydroxysteroid Dehydrogenase Type 14 Nonsteroidal Inhibitors and Crystal Structures in Complex with the EnzymeBraun F, Bertoletti N, Möller G, Adamski J, Steinmetzer T, Salah M, Abdelsamie A, van Koppen C, Heine A, Klebe G, Marchais-Oberwinkler S. First Structure–Activity Relationship of 17β-Hydroxysteroid Dehydrogenase Type 14 Nonsteroidal Inhibitors and Crystal Structures in Complex with the Enzyme. Journal Of Medicinal Chemistry 2016, 59: 10719-10737. PMID: 27933965, DOI: 10.1021/acs.jmedchem.6b01436.